Evidence map›Paper›PMID 42853510›Full record

ArticleAntonie van Leeuwenhoek2026

Comparative antimicrobial activity of crude and partially purified Weissella cibaria NM1 postbiotics against Klebsiella pneumoniae ATCC13382.

Ji King Teh, Cheng Foh Le, Kalavathy Ramasamy, Yin Sze Lim

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ji King TehSchool of Biological and Environmental Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih , Selangor, Malaysia.
Cheng Foh LeSchool of Biological and Environmental Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih , Selangor, Malaysia.
Kalavathy RamasamyFaculty of Pharmacy, Universiti Teknologi MARA (UiTM), 42300, Bandar Puncak Alam, Selangor, Malaysia.
Yin Sze LimSchool of Biological and Environmental Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih , Selangor, Malaysia. yinsze.lim@nottingham.edu.my.

Funding

Ministry of Higher Education Malaysia FRGS/1/2022/SKK12/UNIM/02/3
6 · The paper itself

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is of clinical concern due to its resilience against antibiotics. Among potential alternatives for treatment, postbiotics from lactic acid bacteria (LAB) incite interest due to having strong antimicrobial activities whilst being generally recognised as safe. However, insights into their components and interactions remain limited. Weissella cibaria NM1 produces the proteinaceous postbiotic NM1 that inhibits K. pneumoniae ATCC13382. This study aims to compare the anti-K. pneumoniae activities of crude postbiotic NM1 and its partially-purified protein fractions via minimum inhibitory concentration (MIC) and time-kill assays. The purification of postbiotic NM1 revealed two cationic and six anionic fractions with yields of 0.03-1.08% and purification folds of 0.02-1.47 times. Crude postbiotic NM1 had the lowest MIC at 15.63 mg/mL, as compared to the MICs of its partially purified NM1 fractions at 125-250 mg/mL. The partially purified fractions were bacteriostatic, achieving reductions of 0.07-1.30 log

Indexed as

Anti-Bacterial AgentsKlebsiella pneumoniaeWeissellaMicrobial Sensitivity TestsAnti-Bacterial AgentsKlebsiella pneumoniaeMinimum inhibitory concentrationPostbioticPurificationTime-killWeissella cibaria

Identifiers

PMID42853510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.